Published in Adv Drug Deliv Rev on November 22, 2013
Cell-type-specific, Aptamer-functionalized Agents for Targeted Disease Therapy. Mol Ther Nucleic Acids (2014) 1.32
Multifunctional RNA nanoparticles. Nano Lett (2014) 1.03
MicroRNAs in cancer therapeutic response: Friend and foe. World J Clin Oncol (2014) 0.96
Systemic Delivery of Anti-miRNA for Suppression of Triple Negative Breast Cancer Utilizing RNA Nanotechnology. ACS Nano (2015) 0.91
Triggering of RNA interference with RNA-RNA, RNA-DNA, and DNA-RNA nanoparticles. ACS Nano (2014) 0.88
RNA nanoparticle as a vector for targeted siRNA delivery into glioblastoma mouse model. Oncotarget (2015) 0.87
Extracellular vesicles and their synthetic analogues in aging and age-associated brain diseases. Biogerontology (2014) 0.87
The Role of MicroRNAs in Diabetic Complications-Special Emphasis on Wound Healing. Genes (Basel) (2014) 0.86
CD22ΔE12 as a molecular target for RNAi therapy. Br J Haematol (2015) 0.86
In silico design and enzymatic synthesis of functional RNA nanoparticles. Acc Chem Res (2014) 0.85
RNA as a stable polymer to build controllable and defined nanostructures for material and biomedical applications. Nano Today (2015) 0.84
Human Papillomavirus E6/E7-Specific siRNA Potentiates the Effect of Radiotherapy for Cervical Cancer in Vitro and in Vivo. Int J Mol Sci (2015) 0.82
RNA Nanoparticles Derived from Three-Way Junction of Phi29 Motor pRNA Are Resistant to I-125 and Cs-131 Radiation. Nucleic Acid Ther (2015) 0.79
RNA nanoparticles harboring annexin A2 aptamer can target ovarian cancer for tumor-specific doxorubicin delivery. Nanomedicine (2016) 0.78
Specific Delivery of MiRNA for High Efficient Inhibition of Prostate Cancer by RNA Nanotechnology. Mol Ther (2016) 0.78
The Advancement of the Emerging Field of RNA Nanotechnology. ACS Nano (2017) 0.77
Controllable Self-Assembly of RNA Tetrahedrons with Precise Shape and Size for Cancer Targeting. Adv Mater (2016) 0.77
RNA Nanoparticle-Based Targeted Therapy for Glioblastoma through Inhibition of Oncogenic miR-21. Mol Ther (2017) 0.77
Re-entrant DNA gels. Nat Commun (2016) 0.77
siRNA nanoparticles: the future of RNAi therapeutics for oncology? Nanomedicine (Lond) (2014) 0.76
NANOMEDICINE: will it offer possibilities to overcome multiple drug resistance in cancer? J Nanobiotechnology (2016) 0.76
Innovative delivery of siRNA to solid tumors by super carbonate apatite. PLoS One (2015) 0.75
Post-transcriptional regulation of cytokine and growth factor signaling in cancer. Cytokine Growth Factor Rev (2016) 0.75
A Multi-RNAi Microsponge Platform for Simultaneous Controlled Delivery of Multiple Small Interfering RNAs. Angew Chem Int Ed Engl (2015) 0.75
Bolaamphiphiles as carriers for siRNA delivery: From chemical syntheses to practical applications. J Control Release (2015) 0.75
Engineering Structurally Interacting RNA (sxRNA). Sci Rep (2017) 0.75
Development of dual-activity vectors by co-envelopment of adenovirus and SiRNA in artificial lipid bilayers. PLoS One (2014) 0.75
Controllable self-assembly of RNA dendrimers. Nanomedicine (2015) 0.75
Thermodynamic Features of Structural Motifs Formed by β-L-RNA. PLoS One (2016) 0.75
Mechanism of three-component collision to produce ultrastable pRNA three-way junction of Phi29 DNA-packaging motor by kinetic assessment. RNA (2016) 0.75
Targeted nanoparticles for colorectal cancer. Nanomedicine (Lond) (2016) 0.75
Overcoming Tamoxifen Resistance of Human Breast Cancer by Targeted Gene Silencing using Multifunctional pRNA Nanoparticles. ACS Nano (2016) 0.75
Initial sequencing and analysis of the human genome. Nature (2001) 212.86
MicroRNAs: genomics, biogenesis, mechanism, and function. Cell (2004) 198.59
Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res (2003) 77.89
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature (1998) 72.56
The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell (1993) 64.62
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature (2001) 57.23
MicroRNA signatures in human cancers. Nat Rev Cancer (2006) 46.29
Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science (1990) 35.96
Silencing of microRNAs in vivo with 'antagomirs'. Nature (2005) 32.56
In vitro selection of RNA molecules that bind specific ligands. Nature (1990) 30.19
A stepwise huisgen cycloaddition process: copper(I)-catalyzed regioselective "ligation" of azides and terminal alkynes. Angew Chem Int Ed Engl (2002) 24.12
A species of small antisense RNA in posttranscriptional gene silencing in plants. Science (1999) 19.34
Click Chemistry: Diverse Chemical Function from a Few Good Reactions. Angew Chem Int Ed Engl (2001) 19.25
Crystal structure of the ribosome at 5.5 A resolution. Science (2001) 18.21
Folding DNA to create nanoscale shapes and patterns. Nature (2006) 17.17
Regulation by let-7 and lin-4 miRNAs results in target mRNA degradation. Cell (2005) 15.26
The RNA moiety of ribonuclease P is the catalytic subunit of the enzyme. Cell (1983) 15.26
A DNA-fuelled molecular machine made of DNA. Nature (2000) 13.99
Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer (2005) 13.49
Self-splicing RNA: autoexcision and autocyclization of the ribosomal RNA intervening sequence of Tetrahymena. Cell (1982) 12.12
Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem (2010) 12.06
Design and self-assembly of two-dimensional DNA crystals. Nature (1998) 9.59
UNAFold: software for nucleic acid folding and hybridization. Methods Mol Biol (2008) 6.83
Thermodynamic parameters to predict stability of RNA/DNA hybrid duplexes. Biochemistry (1995) 6.40
Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov (2007) 6.37
Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol (2006) 6.30
Strategies for silencing human disease using RNA interference. Nat Rev Genet (2007) 5.19
siRNA function in RNAi: a chemical modification analysis. RNA (2003) 4.93
Synthesis from DNA of a molecule with the connectivity of a cube. Nature (1991) 4.91
RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol (2010) 4.86
Self-assembly of a nanoscale DNA box with a controllable lid. Nature (2009) 4.62
A robust DNA mechanical device controlled by hybridization topology. Nature (2002) 4.45
RNA mimics of green fluorescent protein. Science (2011) 4.22
Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res (2002) 4.16
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov (2006) 4.03
Targeted deletion of Dicer in the heart leads to dilated cardiomyopathy and heart failure. Proc Natl Acad Sci U S A (2008) 4.00
Structural dynamics of individual Holliday junctions. Nat Struct Biol (2003) 4.00
Riboswitches as versatile gene control elements. Curr Opin Struct Biol (2005) 3.83
Biocompatibility of gold nanoparticles and their endocytotic fate inside the cellular compartment: a microscopic overview. Langmuir (2005) 3.81
Sfold web server for statistical folding and rational design of nucleic acids. Nucleic Acids Res (2004) 3.81
RNAi in human cells: basic structural and functional features of small interfering RNA. Mol Cell (2002) 3.81
Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol (2009) 3.78
U1 snRNP protects pre-mRNAs from premature cleavage and polyadenylation. Nature (2010) 3.65
Building programmable jigsaw puzzles with RNA. Science (2004) 3.51
A nanomechanical device based on the B-Z transition of DNA. Nature (1999) 3.43
NUPACK: Analysis and design of nucleic acid systems. J Comput Chem (2011) 3.33
Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc Natl Acad Sci U S A (2007) 3.30
A small viral RNA is required for in vitro packaging of bacteriophage phi 29 DNA. Science (1987) 3.29
Assembling materials with DNA as the guide. Science (2008) 3.26
Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin Cancer Res (1999) 3.24
Molecular robots guided by prescriptive landscapes. Nature (2010) 3.23
Inter-RNA interaction of phage phi29 pRNA to form a hexameric complex for viral DNA transportation. Mol Cell (1998) 3.21
Topology of three-way junctions in folded RNAs. RNA (2006) 3.14
RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev (2007) 3.13
Riboswitches as antibacterial drug targets. Nat Biotechnol (2006) 3.01
Analysis of RNA motifs. Curr Opin Struct Biol (2003) 2.97
The building blocks and motifs of RNA architecture. Curr Opin Struct Biol (2006) 2.94
Recombinant RNA technology: the tRNA scaffold. Nat Methods (2007) 2.73
The next frontier of molecular medicine: delivery of therapeutics. Nat Med (1998) 2.59
The emerging field of RNA nanotechnology. Nat Nanotechnol (2010) 2.45
Self-assembled RNA interference microsponges for efficient siRNA delivery. Nat Mater (2012) 2.38
TectoRNA: modular assembly units for the construction of RNA nano-objects. Nucleic Acids Res (2001) 2.31
Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp Mol Pathol (2009) 2.25
Fluorescence imaging of cellular metabolites with RNA. Science (2012) 2.23
Controllable self-assembly of nanoparticles for specific delivery of multiple therapeutic molecules to cancer cells using RNA nanotechnology. Nano Lett (2005) 2.22
Counting of six pRNAs of phi29 DNA-packaging motor with customized single-molecule dual-view system. EMBO J (2007) 2.21
Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Res (2005) 2.20
Function of hexameric RNA in packaging of bacteriophage phi 29 DNA in vitro. Mol Cell (1998) 2.13
Chemically modified siRNA: tools and applications. Drug Discov Today (2008) 2.13
Streptavidin aptamers: affinity tags for the study of RNAs and ribonucleoproteins. RNA (2001) 2.11
Thermodynamically stable RNA three-way junction for constructing multifunctional nanoparticles for delivery of therapeutics. Nat Nanotechnol (2011) 2.09
Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells. Nucleic Acids Res (2009) 2.02
The architectonics of programmable RNA and DNA nanostructures. Curr Opin Struct Biol (2006) 2.01
In vitro assembly of cubic RNA-based scaffolds designed in silico. Nat Nanotechnol (2010) 1.96
A new algorithm for RNA secondary structure design. J Mol Biol (2004) 1.96
Bottom-up Assembly of RNA Arrays and Superstructures as Potential Parts in Nanotechnology. Nano Lett (2004) 1.91
Breakthrough of the year. Small RNAs make big splash. Science (2002) 1.85
RNAJunction: a database of RNA junctions and kissing loops for three-dimensional structural analysis and nanodesign. Nucleic Acids Res (2007) 1.83
Specific delivery of therapeutic RNAs to cancer cells via the dimerization mechanism of phi29 motor pRNA. Hum Gene Ther (2005) 1.81
Cell-specific internalization study of an aptamer from whole cell selection. Chemistry (2008) 1.81
Characterization of a "kissing" hairpin complex derived from the human immunodeficiency virus genome. Proc Natl Acad Sci U S A (1994) 1.77
Multilayer DNA origami packed on a square lattice. J Am Chem Soc (2009) 1.74
A dimer as a building block in assembling RNA. A hexamer that gears bacterial virus phi29 DNA-translocating machinery. J Biol Chem (2000) 1.73
Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Crit Rev Ther Drug Carrier Syst (2009) 1.73
RNA nanotechnology: engineering, assembly and applications in detection, gene delivery and therapy. J Nanosci Nanotechnol (2005) 1.68
Nanoparticle surface charges alter blood-brain barrier integrity and permeability. J Drug Target (2004) 1.65
On the stability of nucleic acid structures in solution: enthalpy-entropy compensations, internal rotations and reversibility. Nucleic Acids Res (1993) 1.60
Protein-based nanomedicine platforms for drug delivery. Small (2009) 1.59
Sequence requirement for hand-in-hand interaction in formation of RNA dimers and hexamers to gear phi29 DNA translocation motor. RNA (1999) 1.58
MiR-130a, miR-203 and miR-205 jointly repress key oncogenic pathways and are downregulated in prostate carcinoma. Oncogene (2012) 1.57
RNA tectonics: towards RNA design. Fold Des (1996) 1.57
A role for tRNA modifications in genome structure and codon usage. Cell (2012) 1.57
Bacteriophage DNA packaging: RNA gears in a DNA transport machine. Cell (1998) 1.57
Square-shaped RNA particles from different RNA folds. Nano Lett (2009) 1.57
Small nucleolar RNA signatures as biomarkers for non-small-cell lung cancer. Mol Cancer (2010) 1.56
Systemic trafficking of plant virus nanoparticles in mice via the oral route. Virology (2005) 1.53
Virus-based nanoparticles (VNPs): platform technologies for diagnostic imaging. Adv Drug Deliv Rev (2006) 1.50
Construction of phi29 DNA-packaging RNA monomers, dimers, and trimers with variable sizes and shapes as potential parts for nanodevices. J Nanosci Nanotechnol (2003) 1.50
Self-assembling RNA nanorings based on RNAI/II inverse kissing complexes. Nano Lett (2011) 1.49